VantAI
Xuejin Zhang is an experienced ML/AI scientist currently employed at VantAI, where the focus is on applying AI methods to protein proximity. Prior roles include serving as an AI scientist and computational chemist at PostEra, where responsibilities involved developing advanced models for drug candidate trials, and facilitating data analysis. Xuejin's background also includes a data scientist position at DAI Group, specializing in healthcare and life sciences analytics. The educational journey includes a PhD in Biomathematics, Bioinformatics, and Computational Biology from ETH Zürich, alongside a Master's in Computer-aided drug design and a Bachelor's in Interdisciplinary Pharmaceutical Science from China Pharmaceutical University. Research experience encompasses collaborations with AstraZeneca and Boehringer Ingelheim, focusing on data management and ML model optimization for drug development.
VantAI
1 followers
VantAI pairs bleeding-edge machine learning techniques with deep systems biology expertise to build computational models that uncover hidden relationships between molecules, targets, and diseases. These models power a best-in-class solution that identifies and generates new molecular entities for targets of interest, repurposes existing molecules at any stage of development, uncovers accurate ADME and toxicological insights, and predicts adverse events likely to influence trial success from deep analysis of systems-based pharmacogenomics. VantAI's in silico platform specializes in modelling complex protein-protein interactions, powering the discovery of biologics and protein degraders in addition to small-molecule drugs. It has helped leading biopharma partners launch new development programs--or revitalize old ones--at a fraction of the time and cost of traditional methods.